Business Context and Reporting Period
This Form 8-K filing by Bio-Rad Laboratories, Inc. is dated January 3, 2007. The report addresses a corporate governance event occurring on December 31, 2006, involving the unexpected death of Mr. Philip L. Padou, a longtime Board member and Chairman of the Audit Committee.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance issue and does not contain financial performance data.
Material Changes
The primary material change is the reduction of independent directors on the Audit Committee from three to two due to Mr. Padou's passing. Consequently, the Company voluntarily notified the American Stock Exchange (Amex) on January 3, 2007, that it was not in material compliance with Section 121(B)(2)(a) of the Amex Company Guide, which requires three independent directors on the Audit Committee.
Outlook, Risks, and Management Commentary
Management is actively seeking a replacement for Mr. Padou to restore compliance with Amex listing requirements. In the interim, Mr. Ruediger Naumann-Etienne, a Board member since 2001, has been appointed as the interim Chairman of the Audit Committee. The risk of delisting or failure to satisfy continued listing standards is currently being addressed through this recruitment process.
Key Facts for Investor Verification
- Mr. Philip L. Padou, Chairman of the Audit Committee, passed away on December 31, 2006.
- The Company is currently non-compliant with Amex listing rules regarding the number of independent Audit Committee members.
- Mr. Ruediger Naumann-Etienne serves as the interim Chairman of the Audit Committee.
- The Company is actively searching for a new director to regain full compliance.